EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Comparisons

Sources

Dose Diligence research deskSection 03 · Page 12 of 12Last updated 17 Nov 2026

Primary sources underpin the regulatory, programme, price and technical claims. Trade coverage, job listings and podcast/video searches were used for discovery and question generation, not to establish supplier performance or legal conclusions. URLs below identify the cited records; dynamic pages should be rechecked before a purchasing decision.

Regulation, courts and official guidance

  1. FDA — GLP-1 compounding policy clarification: https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
  2. FDA — Drug Shortages database: https://www.accessdata.fda.gov/scripts/drugshortages/default.cfm
  3. Fifth Circuit — tirzepatide opinion, August 27, 2026: https://www.govinfo.gov/content/pkg/USCOURTS-ca5-25-10600/pdf/USCOURTS-ca5-25-10600-0.pdf
  4. Fifth Circuit — semaglutide opinion, revised September 1, 2026: https://www.govinfo.gov/content/pkg/USCOURTS-ca5-25-10758/pdf/USCOURTS-ca5-25-10758-0.pdf
  5. FDA — proposed exclusion from 503B bulks list: https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
  6. FDA — concerns with unapproved GLP-1 drugs: https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  7. FDA — 503A essentially-copy guidance: https://www.fda.gov/media/98973/download
  8. FDA — prescription requirement under 503A: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/prescription-requirement-under-section-503a-federal-food-drug-and-cosmetic-act-guidance-industry
  9. FDA — 503A and 503B statutory-framework presentation: https://www.fda.gov/media/162166/download
  10. US Code — 21 USC 353b: https://www.govinfo.gov/content/pkg/USCODE-2024-title21/html/USCODE-2024-title21-chap9-subchapV-partA-sec353b.htm
  11. FDA — compounding questions and answers: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
  12. FDA — registered outsourcing facilities: https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities
  13. FDA — Form 483 FAQs: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-references/fda-form-483-frequently-asked-questions
  14. FDA — wholesale distributor and logistics-provider reporting: https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/annual-licensure-reporting-wholesale-drug-distributors-and-third-party-logistics-providers
  15. FDA — DSCSA exemptions: https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/exemptions-under-drug-supply-chain-security-act
  16. California Board of Pharmacy — nonresident licensing: https://www.pharmacy.ca.gov/applicants/phy.shtml
  17. California Board of Pharmacy — July 2026 requirements: https://www.pharmacy.ca.gov/applicants/new_requirements_nrp.shtml
  18. California Board of Pharmacy — nonresident sterile-compounding application: https://www.pharmacy.ca.gov/forms/nrp_comp_app_pkt.pdf
  19. CMS — Medicare GLP-1 Bridge: https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge
  20. HHS — business-associate guidance: https://www.hhs.gov/hipaa/for-professionals/privacy/guidance/business-associates/index.html
  21. FDA — November 9, 2026 safety communication: https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential

Manufacturer programmes and supplier documentation

  1. LillyDirect — patient FAQs: https://www.lilly.com/lillydirect/faq
  2. LillyDirect — Zepbound access and pricing: https://www.lilly.com/lillydirect/zepbound
  3. LillyDirect — Zepbound full terms: https://www.lilly.com/lillydirect/zepbound/zepbound-tirzepatide-full-terms-conditions
  4. LillyDirect — Foundayo access and pricing: https://www.lilly.com/lillydirect/foundayo
  5. NovoCare — healthcare-professional delivery information: https://www.novocare.com/hcp/delivery.html
  6. NovoCare — current Wegovy savings offers: https://www.novocare.com/patient/medicines/wegovy/savings-offer.html
  7. NovoCare — Wegovy price guide, including historical promotional footnotes: https://www.novocare.com/content/dam/novonordisk/novocare/redesign/pdf/Wegovy_Price_Guide.pdf
  8. McKesson — pharmaceutical distribution: https://www.mckesson.com/business-solutions/pharmaceutical-medical-products-distribution/pharmaceutical-distribution-services/
  9. Photon — product FAQ: https://photonhealth.com/faq
  10. Photon — order and prescription status definitions: https://docs.photon.health/docs/order-rx-status-retail-pharmacycourier-delivery

Limitations: Public evidence does not establish negotiated acquisition prices, facility-level available capacity, account approval, all-state permissions or comparative service outcomes. This document is procurement decision support, not legal clearance or individual medical advice.

Sources cited on this page

  1. fda.gov · Source 1 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
  2. accessdata.fda.gov · Source 2 ↗https://www.accessdata.fda.gov/scripts/drugshortages/default.cfm
  3. govinfo.gov · Source 3 ↗https://www.govinfo.gov/content/pkg/USCOURTS-ca5-25-10600/pdf/USCOURTS-ca5-25-10600-0.pdf
  4. govinfo.gov · Source 4 ↗https://www.govinfo.gov/content/pkg/USCOURTS-ca5-25-10758/pdf/USCOURTS-ca5-25-10758-0.pdf
  5. fda.gov · Source 5 ↗https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
  6. fda.gov · Source 6 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  7. fda.gov · Source 7 ↗https://www.fda.gov/media/98973/download
  8. fda.gov · Source 8 ↗https://www.fda.gov/regulatory-information/search-fda-guidance-documents/prescription-requirement-under-section-503a-federal-food-drug-and-cosmetic-act-guidance-industry
  9. fda.gov · Source 9 ↗https://www.fda.gov/media/162166/download
  10. govinfo.gov · Source 10 ↗https://www.govinfo.gov/content/pkg/USCODE-2024-title21/html/USCODE-2024-title21-chap9-subchapV-partA-sec353b.htm
  11. fda.gov · Source 11 ↗https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
  12. fda.gov · Source 12 ↗https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities
  13. fda.gov · Source 13 ↗https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-references/fda-form-483-frequently-asked-questions
  14. fda.gov · Source 14 ↗https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/annual-licensure-reporting-wholesale-drug-distributors-and-third-party-logistics-providers
  15. fda.gov · Source 15 ↗https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/exemptions-under-drug-supply-chain-security-act
  16. pharmacy.ca.gov · Source 16 ↗https://www.pharmacy.ca.gov/applicants/phy.shtml
  17. pharmacy.ca.gov · Source 17 ↗https://www.pharmacy.ca.gov/applicants/new_requirements_nrp.shtml
  18. pharmacy.ca.gov · Source 18 ↗https://www.pharmacy.ca.gov/forms/nrp_comp_app_pkt.pdf
  19. cms.gov · Source 19 ↗https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge
  20. hhs.gov · Source 20 ↗https://www.hhs.gov/hipaa/for-professionals/privacy/guidance/business-associates/index.html
  21. fda.gov · Source 21 ↗https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential
  22. lilly.com · Source 22 ↗https://www.lilly.com/lillydirect/faq
  23. lilly.com · Source 23 ↗https://www.lilly.com/lillydirect/zepbound
  24. lilly.com · Source 24 ↗https://www.lilly.com/lillydirect/zepbound/zepbound-tirzepatide-full-terms-conditions
  25. lilly.com · Source 25 ↗https://www.lilly.com/lillydirect/foundayo
  26. novocare.com · Source 26 ↗https://www.novocare.com/hcp/delivery.html
  27. novocare.com · Source 27 ↗https://www.novocare.com/patient/medicines/wegovy/savings-offer.html
  28. novocare.com · Source 28 ↗https://www.novocare.com/content/dam/novonordisk/novocare/redesign/pdf/Wegovy_Price_Guide.pdf
  29. mckesson.com · Source 29 ↗https://www.mckesson.com/business-solutions/pharmaceutical-medical-products-distribution/pharmaceutical-distribution-services/
  30. photonhealth.com · Source 30 ↗https://photonhealth.com/faq
  31. docs.photon.health · Source 31 ↗https://docs.photon.health/docs/order-rx-status-retail-pharmacycourier-delivery
Section sources →